Date of submission: 22/08/2023

Breast Carcinoma

HBCx-2

Model characterisation

Provided by

Institut Curie - LIP - BC

View data at Curie-BC Contact Curie-BC

License: EMBL-EBI

Patient / Tumour Metadata

Patient Sex
female
Patient Age
70 - 79
Patient Ethnicity
Not Provided
Tumour Type
Metastatic
Cancer Grade
Grade 3
Cancer Stage
T2N1M1
Primary Site
breast
Collection Site
lymph node

PDX model engraftment

PDX model engraftment
HOST STRAIN NAME	SITE	TYPE	MATERIAL	MATERIAL STATUS	PASSAGE
swiss nude	Inter-scapular	Heterotopic	Tissue Fragment	Fresh	all

Model quality control

Model quality control
TECHNIQUE	DESCRIPTION	PASSAGE
Histology	high concordance between xenograft and patient tumour	1,2
Fingerprinting	high concordance between xenograft and patient tumour	22

Model treatment

Model treatment
DRUG	DOSE	PASSAGE	RESPONSE
Doxorubicin Hydrochloride ChEMBL PubChem Cyclophosphamide ChEMBL PubChem	2 mg/kg 100 mg/kg	4 4	Progressive Disease Progressive Disease
Paclitaxel ChEMBL PubChem	20 mg/kg	12	Not Provided
Capecitabine ChEMBL PubChem	2x270 mg/kg	5	Progressive Disease
CPT11 PubChem	50 mg/kg	60	Progressive Disease
Cisplatin ChEMBL PubChem	6 mg/kg	45	Progressive Disease
Everolimus ChEMBL PubChem	2.5 mg/kg	45	Progressive Disease
Docetaxel ChEMBL PubChem	20 mg/kg	8	Progressive Disease
Olaparib ChEMBL PubChem	100 mg/kg	56.22	Progressive Disease

Patient treatment

Patient treatment
TREATMENT	DOSE	RESPONSE
Lymphadenectomy Mastectomy	not provided not provided	Progressive Disease Progressive Disease